BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Barclays (LON:BARC) has raised its price target on Livanova (NASDAQ:LIVN) to $58.00 from $55.00 while maintaining an Equalweight rating on the medical technology company’s stock. The stock currently trades at $53.39, near its 52-week high of $57.35, with analyst targets ranging from $56 to $80. According to InvestingPro data, the company maintains a "GREAT" financial health score of 3.13 out of 5.
The price target increase reflects Barclays’ upward revision of sales projections by approximately 3% for 2025, aligning with management’s commentary and updated outlook. The firm has also raised its sales projections by approximately 9% on average per year for 2026 and beyond. InvestingPro analysis reveals that 6 analysts have revised their earnings upwards for the upcoming period, and the company’s revenue grew by 8.2% over the last twelve months.
Barclays has similarly adjusted its earnings per share (EPS) estimates, increasing them by approximately 3% for 2025 and by 5-6% on average per year for 2026 and beyond. These revisions follow what Barclays described as a "strong beat on sales and EPS" in Livanova’s second-quarter results, published on August 6.
The new $58 price target is based on an 8.0x EV/EBITDA multiple on Barclays’ projected next-twelve-months EBITDA of $396 million, up from the previous estimate of $385 million.
Barclays notes that its target multiple represents a slight premium to Livanova’s current multiple of approximately 7.0x and is roughly in line with the stock’s year-to-date multiple of approximately 8.0x.
In other recent news, LivaNova PLC reported impressive second-quarter results for 2025, with earnings per share (EPS) significantly exceeding expectations. The company achieved an EPS of $1.05, surpassing the forecast of $0.87 by 20.69%. Additionally, LivaNova’s revenue reached $353 million, outperforming the anticipated $332.21 million. These strong financial results highlight the company’s positive performance in the recent quarter. There was no mention of mergers or acquisitions in the recent updates. Analyst upgrades or downgrades were also not reported. The focus remains on the earnings and revenue results as the primary highlights for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.